[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338260-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-338260-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","myc-is-sufficient-to-generate-mid-life-high-grade-serous-ovarian-and-uterine-serous-carcinomas-in-a-p53-r270h-mouse-model","MYC is Sufficient to Generate Mid-Life High-Grade Serous Ovarian and Uterine Serous Carcinomas in a p53-R270H Mouse Model","","Genetically engineered mouse models (GEMMs) reshape understanding of ovarian cancer etiology, early detection, and treatment. This study uses MYC, a frequently amplified oncogene in high-grade serous ovarian cancer (HGSOC), by coupling Myc with dominant-negative p53-R270H and an Ovgp1 fallopian tube epithelium promoter to create a new HGSOC GEMM. Female mice develop lethal tumors in about 14.5 months, with HGSOC-like histology and nuclear p53/MYC clusters in fallopian tube and ovarian surface epithelium.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/myc-is-sufficient-to-generate-mid-life-high-grade-serous-ovarian-and-uterine-serous-carcinomas-in-a-p53-r270h-mouse-model/338260/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/myc-is-sufficient-to-generate-mid-life-high-grade-serous-ovarian-and-uterine-serous-carcinomas-in-a-p53-r270h-mouse-model/338260.png","ImageObject",300,407,{"name":42,"@type":43},"Miles","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How was the new mouse model for HGSOC generated?","Question",{"text":63,"@type":64},"The study coupled Myc with a dominant-negative p53-R270H mutant and used an Ovgp1 fallopian tube epithelium-specific promoter to generate a new GEMM of HGSOC.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What tumor phenotype and timeline did the female mice show?",{"text":68,"@type":64},"Female mice developed lethal cancer at an average of 14.5 months. Histopathology showed HGSOC characteristics including nuclear p53 and nuclear MYC clustered expression in fallopian tube epithelium and ovarian surface epithelium.",{"name":70,"@type":61,"acceptedAnswer":71},"What unexpected finding links the model to uterine serous cancer?",{"text":72,"@type":64},"Nuclear p53 and MYC clustered expression was also identified in the uterine luminal epithelium, suggesting possible intraepithelial metastasis from the fallopian tube and supporting that uterine serous cancer may originate there.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},338260,1790760906,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-24-0144](https://doi.org/10.1158/2767-9764.CRC-24-0144)  OPEN ACCESS  \nMYC is Sufficient to Generate Mid-Life  \nHigh-Grade Serous Ovarian and Uterine Serous Carcinomas in a p53-R270H Mouse Model  \nAlexandra Blackman1, Amy C. Rees2, Robert R. Bowers2, Christian M. Jones2, Silvia G. Vaena3,  \nMadison A. Clark2, Shelby Carter4, Evan D. Villamor2, Della Evans2, Anthony J. Emanuel4, George Fullbright2, Matthew S. O’Malley5, Richard L. Carpenter5,6, David T. Long2, Laura S. Spruill4, Martin J. Romeo3,  \nBrian C. Orr1, Kristi L. Helke7, and Joe R. Delaney2  \nABSTRACT  \n􀀶  \nGenetically engineered mouse models (GEMM) have fundamentally changed how ovarian cancer etiology, early detection, and treatment are understood. MYC, an oncogene, is amongst the most amplified genes in high-grade serous ovarian cancer (HGSOC), but it has not previously been utilized to drive HGSOC GEMMs. We coupled Myc and dominantnegative mutant p53-R270H with a fallopian tube epithelium (FTE) -specific promoter Ovgp1 to generate a new GEMM of HGSOC. Female mice developed lethal cancer at an average of 14.5 months. Histopathologic examination of mice revealed HGSOC characteristics, including nuclear p53 and nuclear MYC in clusters of cells within the FTE and ovarian surface epithelium. Unexpectedly, nuclear p53 and MYC clustered cell expression was also identified in the uterine luminal epithelium, possibly from intraepithelial metastasis from the FTE. Extracted tumor cells exhibited strong loss of heterozygosity at the p53 locus, leaving the mutant allele. Copy-number alterations in these cancer cells  \nwere prevalent, disrupting a large fraction of genes. Transcriptome profiles most closely matched human HGSOC and serous endometrial cancer. Taken together, these results demonstrate that the Myc and Trp53-R270H transgenes were able to recapitulate many phenotypic hallmarks of HGSOC through the utilization of strictly human-mimetic genetic hallmarks of HGSOC. This new mouse model enables further exploration of ovarian cancer pathogenesis, particularly in the 50% of HGSOC which lack homology-directed repair mutations. Histologic and transcriptomic findings are consistent with the hypothesis that uterine serous cancer may originate from the FTE.  \nSignificance: Mouse models using transgenes which generate spontaneous cancers are essential tools to examine the etiology of human diseases. Here, the first Myc-driven spontaneous model is described as a valid HGSOC model. Surprisingly, aspects of uterine serous carcinoma were also observed in this model.  \n1Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, South Carolina. 2Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina. 3Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina. 4Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina. 5Department of Medical Sciences, Indiana University Bloomington, Bloomington, Indiana. 6Department of Biochemistry and Molecular Biology, Indiana University Bloomington, Bloomington, Indiana. 7Department of Comparative Medicine, Medical University of South Carolina, Charleston, South Carolina.  \nA. Blackman, A.C. Rees, R. R. Bowers, and C. M. Jones contributed equally to this article.  \nCorresponding Author: Joe R. Delaney, Department of Biochemistry and Molecular Biology, Medical University of South Carolina, 173 Ashley Avenue, Charleston, SC 29425. E-mail: [delaneyj@musc.edu](delaneyj@musc.edu)  \n[doi:](doi: 10.1158/2767-9764)[ 10.1158/2767-9764](doi: 10.1158/2767-9764) .CRC-24-0144  \nThis open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4. 0) license.  \n©2024 The Authors; Published by the American Association for Cancer Research  \nIntroduction  \nGynecologic oncology has only recently be","cbCaiusfUhrIGMHn","https://ap.wps.com/l/cbCaiusfUhrIGMHn","pdf",54449158,14,"English","# Abstract\n## Introduction\n## Targeted therapies and molecular context\n## Genetically engineered mouse models (GEMMs)","[{\"question\":\"How was the new mouse model for HGSOC generated?\",\"answer\":\"The study coupled Myc with a dominant-negative p53-R270H mutant and used an Ovgp1 fallopian tube epithelium-specific promoter to generate a new GEMM of HGSOC.\"},{\"question\":\"What tumor phenotype and timeline did the female mice show?\",\"answer\":\"Female mice developed lethal cancer at an average of 14.5 months. Histopathology showed HGSOC characteristics including nuclear p53 and nuclear MYC clustered expression in fallopian tube epithelium and ovarian surface epithelium.\"},{\"question\":\"What unexpected finding links the model to uterine serous cancer?\",\"answer\":\"Nuclear p53 and MYC clustered expression was also identified in the uterine luminal epithelium, suggesting possible intraepithelial metastasis from the fallopian tube and supporting that uterine serous cancer may originate there.\"}]","MYC is Sufficient to Generate Mid-Life High-Grade Serous Ovarian and Uterine Serous Carcinomas in a p53-R270H Mouse Model | PDF",1790022799,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2ac014b576e7c3025ca52a21ffc59f37.webp",983,1263,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c940351a0d071273c6d62a083566d954.webp",982,1262,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0bdcd1ef51913386a4f6510a763c5865.webp",981,1261,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8a1ae8efc58857a0d6d029ed9fba631f.webp",980,1259]